<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03506789</url>
  </required_header>
  <id_info>
    <org_study_id>SM1-KAKG-2018</org_study_id>
    <nct_id>NCT03506789</nct_id>
  </id_info>
  <brief_title>Dexamethasone Twice for Pain Treatment of Total Knee Arthroplasty</brief_title>
  <acronym>DEX-2-TKA</acronym>
  <official_title>Dexamethasone Twice for Pain Treatment of Total Knee Arthroplasty - A Randomized Blinded Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Naestved Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Naestved Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dexamethasone twice for pain treatment after total knee arthroplasty - A Placebo-controlled,&#xD;
      randomised, parallel 3-group multicentre trial of one and two doses of dexamethasone for&#xD;
      postoperative treatment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial name: Dexamethasone twice for pain treatment of total knee arthroplasty - A randomized&#xD;
      blinded placebo-controlled clinical trial&#xD;
&#xD;
      Trial Acronym: DEX-2-TKA&#xD;
&#xD;
      Background: Effective postoperative pain management is essential for the well-being and&#xD;
      rehabilitation of the surgical patient. No &quot;gold standard&quot; exists for pain treatment after&#xD;
      total knee arthroplasty (TKA) since combinations of different analgesic treatments are used&#xD;
      with nearly no evidence for combined analgesic efficacy. A single perioperative dose of&#xD;
      glucocorticoid (GCC) (i.e. dexamethasone) has well established effects on postoperative&#xD;
      nausea and vomiting, and may be beneficial for postoperative pain. A recent trial suggested&#xD;
      that an additional postoperative dose of GCC improved postoperative pain treatment. Recent&#xD;
      systematic reviews, sub-studies of RCTs and cohort studies of perioperative GCC raised no&#xD;
      concern regarding serious adverse events of a single dose GCC for non-cardiac surgery.&#xD;
      However, optimal dose, combination and regimen of perioperative GCC remains unsettled.&#xD;
&#xD;
      Objective: To establish the analgesic effect and safety of one and two consecutive days of a&#xD;
      single dose of dexamethasone after TKA. GCC will be administered in combination with&#xD;
      paracetamol, NSAID (ibuprofen), and local infiltration analgesia.&#xD;
&#xD;
      Intervention: The participants will be randomised in three groups: A) 24 mg dexamethasone&#xD;
      i.v. perioperative (POD0) and 24 mg dexamethasone i.v. on the first postoperative day (POD1);&#xD;
      B) 24 mg dexamethasone i.v. POD0 and placebo (isotonic saline) i.v. on POD1; and C) placebo&#xD;
      i.v. on POD0 and POD1.&#xD;
&#xD;
      Design and trial size: Placebo-controlled, randomised, parallel 3-group multicentre trial&#xD;
      with adequate centralised computer-generated allocation sequence and allocation concealment&#xD;
      with unknown block size. Assessor, investigator, caregivers and participants will all be&#xD;
      blinded. A total of 423 eligible participants are needed to detect a difference of 10 mg&#xD;
      morphine for the first 48 hours postoperatively with a standard deviation of 23 mg, an&#xD;
      overall familywise type 1 error rate of 0.05 and a type 2 error rate of 0.10. To compensate&#xD;
      for uncertainty of the distribution a surplus of 15 % is added, thus a total of 486 patients&#xD;
      will be included. To maintain an overall familywise error rate of 0.05 the sample size&#xD;
      estimation is based on pairwise comparisons of the primary outcome between the three groups&#xD;
      (three comparisons) with an individual type I error rate of 0.0167.&#xD;
&#xD;
      Sub studies: The investigators plan the following substudies&#xD;
&#xD;
        -  One-year follow-up with EQ-5D-5L (EuroQuols - 5 dimension - 5 level score),&#xD;
           Oxford-Knee-Score and mortality including need for medical attention.&#xD;
&#xD;
        -  Troponin (TnI) levels 24 and 48 hours postoperatively (only at Naestved Hospital).&#xD;
&#xD;
        -  Analysis of high and low pain responders.&#xD;
&#xD;
        -  Establishment of a bio-bank (blood-samples) for future studies (only at Naestved&#xD;
           Hospital).&#xD;
&#xD;
      Due to decisions made by the Steering Committee at our meeting the 14th of May 2019 in Køge,&#xD;
      Region Zealand, Denmark, the secondary outcomes have been rearranged and divided into&#xD;
      secondary outcomes and other (eksplorative) outcomes. Furthermore an additional explorative&#xD;
      endpoint is added: Number of patients with a permanent use of opioids 90 days after surgery.&#xD;
&#xD;
      No data was unblinded or analyzed to aid the decisions.&#xD;
&#xD;
      After the last patient was included, but prior to data analysis and unmasking, the Steering&#xD;
      Committee decided to include the following explorative outcomes in the main article reporting&#xD;
      results from this trial. The decision was made by consensus via email 4th of October 2020:&#xD;
&#xD;
        -  proportion of participants with one or more severe adverse event (SAE), including death,&#xD;
           within 90 days after surgery (SAE defined according to ICH-GCP-guidelines, except&#xD;
           'prolongation of hospitalisation')&#xD;
&#xD;
        -  opioid related adverse events (AE)&#xD;
&#xD;
             -  level of nausea, sedation and dizziness at 24 and 48 h&#xD;
&#xD;
             -  number of vomiting episodes 0-24 and 24-48 h&quot;&#xD;
&#xD;
             -  use of anti-emetics 0-24 and 24-48 h&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 14, 2018</start_date>
  <completion_date type="Actual">June 7, 2020</completion_date>
  <primary_completion_date type="Actual">March 11, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative usage of morphine 0-48 hours postoperatively</measure>
    <time_frame>0-48 hours postoperatively</time_frame>
    <description>Morphine administered both as patient-controlled analgesia (PCA) i.v. morphine 0-24 hours and oral morphine on demand 24-48 hours, and any other supplemental morphine administered postoperatively.&#xD;
Consumption in mg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VAS-pain scores (visual analogue scale (VAS))</measure>
    <time_frame>24 and 48 hours postoperatively</time_frame>
    <description>with active 45 degrees flexion of the knee (VAS) at 24 and 48 hours postoperatively&#xD;
at rest at 24 and 48 hours postoperatively&#xD;
highest score during 0-24 hours and 24-48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events, patient-reported</measure>
    <time_frame>0-48 hours postoperatively</time_frame>
    <description>Number of patients with one or more patient-reported adverse event in the intervention period</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients with one or more serious adverse events (SAE)</measure>
    <time_frame>90 days postoperatively</time_frame>
    <description>Number of patients with one or more serious adverse events (SAE), including death, within 90 days after surgery defined as SAE (according to ICH-GCP-guidelines), except &quot;prolongation of hospitalisation&quot;</description>
  </other_outcome>
  <other_outcome>
    <measure>90 days follow-up</measure>
    <time_frame>90 days postoperatively</time_frame>
    <description>Number of patients with need for medical attention and/or intervention including need for anti-biotics and/or re-operation</description>
  </other_outcome>
  <other_outcome>
    <measure>Total need of i.v. morphine 0-24 hours postoperatively</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
    <description>Consumption in mg</description>
  </other_outcome>
  <other_outcome>
    <measure>Total need of oral morphine 24-48 hours postoperatively</measure>
    <time_frame>24-48 hours postoperatively</time_frame>
    <description>Consumption in mg</description>
  </other_outcome>
  <other_outcome>
    <measure>VAS-pain scores (visual analogue scale (VAS))</measure>
    <time_frame>6, 24 and 48 hours postoperatively hours postoperatively</time_frame>
    <description>with active 45 degrees flexion of the knee (VAS) at 6 hours postoperatively&#xD;
at rest at 6 postoperatively&#xD;
average score during 0-24 hours and 24-48 hours</description>
  </other_outcome>
  <other_outcome>
    <measure>Timed up and go (TUG) test at 24 and 48 hours including maximum pain during the TUG test.</measure>
    <time_frame>24 and 48 hours postoperatively</time_frame>
    <description>The timed up and go test is performed at 24 and 48 hours postoperatively. The participant will be placed on a chair, 3 meters from a line. After the command &quot;Go&quot; the participant will&#xD;
Stand up from the chair&#xD;
Walk to the line on the floor&#xD;
Turn&#xD;
Walk back to the chair&#xD;
Sit down again.&#xD;
The time will be measured from &quot;Go&quot; to the participant is sitting again.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events, nausea</measure>
    <time_frame>0-48 hours postoperatively</time_frame>
    <description>Level of nausea at 6, 24 and 48 hours postoperatively&#xD;
Scale: none, mild, moderate, severe</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events, sedation</measure>
    <time_frame>0-48 hours postoperatively</time_frame>
    <description>Level of sedation at 6, 24 and 48 hours postoperatively&#xD;
Scale: none, mild, moderate, severe</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events, dizziness</measure>
    <time_frame>0-48 hours postoperatively</time_frame>
    <description>Level of dizziness at 6, 24 and 48 hours postoperatively&#xD;
Scale: none, mild, moderate, severe</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events, vomiting</measure>
    <time_frame>0-48 hours postoperatively</time_frame>
    <description>Number of vomiting episodes (0-48 hours) measured in the periods 0-24 and 24-48 hours postoperatively</description>
  </other_outcome>
  <other_outcome>
    <measure>Consumption of antiemetics in the period 0-24 and 24-48 hours postoperatively</measure>
    <time_frame>0-48 hours postoperatively</time_frame>
    <description>Use of ondansetron and DHB (Dehydrobenzperidol)</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of sleep 0-24 and 24-48 hours postoperatively</measure>
    <time_frame>0-48 hours postoperatively</time_frame>
    <description>Scale: very bad, fairly bad, fairly good, very good</description>
  </other_outcome>
  <other_outcome>
    <measure>Level of fatigue at 24 and 48 hours postoperatively</measure>
    <time_frame>24 and 48 hours postoperatively</time_frame>
    <description>Scale: none, mild, moderate, severe</description>
  </other_outcome>
  <other_outcome>
    <measure>NRS-pain scores 3-7 days postoperatively</measure>
    <time_frame>3-7 days postoperatively</time_frame>
    <description>Two daily NRS-scores: One in the morning and one in the evening</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of sleep 3-7 days postoperatively</measure>
    <time_frame>3-7 days postoperatively</time_frame>
    <description>Scale: very bad, fairly bad, fairly good, very good</description>
  </other_outcome>
  <other_outcome>
    <measure>Satisfaction with postoperative pain treatment after 7 days</measure>
    <time_frame>7 days postoperatively</time_frame>
    <description>Scale: very bad, fairly bad, fairly good, very good</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of participants with permanent use of opioids 90 days after surgery</measure>
    <time_frame>90 days postoperatively</time_frame>
    <description>Number of patients with prescripción for painkillers</description>
  </other_outcome>
  <other_outcome>
    <measure>90 days follow-up using EQ5D5L</measure>
    <time_frame>90 days postoperatively</time_frame>
    <description>Qualitative participant reported assessments using EQ5D5L (Questionaire - with one NRS (0-100))</description>
  </other_outcome>
  <other_outcome>
    <measure>90 days follow-up using Oxford-Knee-Score</measure>
    <time_frame>90 days postoperatively</time_frame>
    <description>Qualitative participant reported assessments using Oxford-Knee-Score (Questionaire, scale 12-60 points)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">485</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Treatment A:</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 mg dexamethasone i.v. perioperatively and 24 mg dexamethasone i.v. on the first postoperative day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B:</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 mg dexamethasone i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (isotonic saline) i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 24 mg</description>
    <arm_group_label>Treatment A:</arm_group_label>
    <arm_group_label>Treatment B:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Isotonic saline</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Treatment B:</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled for unilateral, primary total knee arthroplasty&#xD;
&#xD;
          -  ASA 1-3&#xD;
&#xD;
          -  BMI ≥ 18.0 and ≤ 40.0&#xD;
&#xD;
          -  Negative urine HCG pregnancy test and use of anti-conception for women in the fertile&#xD;
             age&#xD;
&#xD;
          -  Patients who gave their written informed consent to participating in the trial after&#xD;
             having fully understood the contents of the protocol and restrictions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who cannot cooperate with the trial&#xD;
&#xD;
          -  Concomitant participation in another trial involving medication&#xD;
&#xD;
          -  Patients who cannot understand or speak Danish&#xD;
&#xD;
          -  Patients with allergy to medication used in the trial&#xD;
&#xD;
          -  Patients with daily use of high dose opioid (&gt; oral morphine 30 mg/day or oxycodone 30&#xD;
             mg/day or tramadol 150 mg/day) or any use of other opioids including methadone and&#xD;
             transdermal opioids.&#xD;
&#xD;
          -  Patients with at daily use of systemic glucocorticoids&#xD;
&#xD;
          -  Contraindications against ibuprofen or paracetamol, for example previous ulcer, known&#xD;
             heart failure, known liver failure, or known renal failure (eGRF &lt; 60 ml/kg/1,73m2),&#xD;
             known thrombocytopenia (&lt;100 bil/l); or against treatment with glucocorticoids.&#xD;
&#xD;
          -  Dysregulated diabetes (investigators judgement)&#xD;
&#xD;
          -  Patients suffering from alcohol and/or drug abuse - based on the investigator's&#xD;
             judgement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ole Mathiesen, MD, PhD, Assoc Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anaesthesiology, Zealand University Hospital, Køge</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Hägi-Pedersen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anaesthesiology, Næstved Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jørgen B Dahl, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anaesthesiology, Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kasper S Gasbjerg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anaesthesiology, Næstved Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Troels H Lunn, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anaesthesiology, Bispebjerg Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gildhøj Privathospital</name>
      <address>
        <city>Brøndbyvester</city>
        <zip>2605</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sjællands Universitetshospital, Køge</name>
      <address>
        <city>Køge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Næstsved Sygehus</name>
      <address>
        <city>Næstved</city>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 21, 2018</study_first_submitted>
  <study_first_submitted_qc>April 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2018</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will also be published anonymised according to ICIMEs (International Committee of Medical Journal Editors) guidelines</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

